# LUX-Lung 3 (NCT00949650)

> BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

No report yet. It can be ordered.

- Drugs tested: afatinib
- Indication: first-line EGFR mutation-positive advanced lung adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00949650
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Boehringer Ingelheim
- Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
- Interventions: Pemetrexed; BIBW 2992; Cisplatin
- Enrollment: 345
- Primary outcome: Progression-Free Survival (PFS) Time

## Indexed commentary on LUX-Lung 3 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 21 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lux-lung-3-nct00949650

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00949650", "email": "<work email>"}; the inbox owner confirms by the emailed link.
